A crystallisation development workflow for the manufacturability improvement of active pharmaceutical ingredients

H. Siddique, N. Hamilton, M. Robertson, M. Warzecha, K. Smith, C. Brown, B. Johnston, A. J. Florence, S. Douieb, E. Hadjittofis, G. Assaf, N. Carly, M. Pasha, U. Cocchini, J. Mantanus

Research output: Contribution to conferencePoster

1 Downloads (Pure)

Abstract

More than 70% active pharmaceutical ingredients (APIs), in the development pipeline, exhibit poor manufacturability (e.g., Isolation, flowability, tabletability) posing major challenges in the production of consistent product with desired performance1. Crystallisation is a key operation in the isolation of the majority of pharmaceuticals and has been demonstrated as a critical process to improve manufacturability of the drug.
Original languageEnglish
Pages49-49
Number of pages1
Publication statusPublished - 16 May 2022
EventCMAC Annual Open Day 2022 - Glasgow, United Kingdom
Duration: 16 May 202218 May 2022

Conference

ConferenceCMAC Annual Open Day 2022
Country/TerritoryUnited Kingdom
CityGlasgow
Period16/05/2218/05/22

Keywords

  • active pharmaceutical ingredients
  • manufacturability
  • crystallisation

Fingerprint

Dive into the research topics of 'A crystallisation development workflow for the manufacturability improvement of active pharmaceutical ingredients'. Together they form a unique fingerprint.

Cite this